📊 SGHT Key Takeaways
Is Sight Sciences, Inc. (SGHT) a Good Investment?
Sight Sciences exhibits strong gross margins (86.2%) characteristic of medical device companies, but is fundamentally unprofitable with -$38.4M net losses and declining revenue (-3.1% YoY). The company burns approximately $30M annually from operations, though a $92M cash position provides ~3 years of runway, indicating a pre-profitability company without demonstrated commercial traction.
Why Buy Sight Sciences, Inc. Stock? SGHT Key Strengths
- Exceptional gross margin of 86.2% demonstrates strong product value and pricing power in medical device market
- Robust cash position of $92M provides substantial runway and eliminates near-term solvency risk
- Excellent liquidity ratios (10.22x current ratio, 9.52x quick ratio) indicate strong financial flexibility and no working capital stress
SGHT Stock Risks: Sight Sciences, Inc. Investment Risks
- Declining revenue (-3.1% YoY) signals failing commercialization or market demand despite capital availability
- Severe operating cash burn (-$29.7M annually) with negative free cash flow unsustainable without revenue recovery
- Flat net income YoY (-$38.4M) despite gross margin strength indicates operating expenses cannot be controlled; no visible path to profitability
- Negative returns on equity (-60.1%) and assets (-33.3%) demonstrate capital is not being productively deployed
Key Metrics to Watch
- Revenue growth trajectory - must demonstrate YoY growth to validate market adoption
- Operating cash flow burn rate - sustainability of current $30M annual cash burn relative to runway
- Gross margin maintenance - ensure 86% level persists as company scales
- Operating expense ratio - critical need for OpEx discipline to approach profitability at current revenue levels
Sight Sciences, Inc. (SGHT) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 10.22x current ratio provides a solid financial cushion.
SGHT Profit Margin, ROE & Profitability Analysis
SGHT vs Healthcare Sector: How Sight Sciences, Inc. Compares
How Sight Sciences, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Sight Sciences, Inc. Stock Overvalued? SGHT Valuation Analysis 2026
Based on fundamental analysis, Sight Sciences, Inc. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Sight Sciences, Inc. Balance Sheet: SGHT Debt, Cash & Liquidity
SGHT Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Sight Sciences, Inc.'s revenue has grown significantly by 63% over the 5-year period, indicating strong business expansion. The most recent EPS of $-1.03 indicates the company is currently unprofitable.
SGHT Revenue Growth, EPS Growth & YoY Performance
SGHT Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $19.9M | -$8.2M | $-0.16 |
| Q2 2025 | $19.6M | -$11.9M | $-0.23 |
| Q1 2025 | $17.5M | -$14.2M | $-0.28 |
| Q3 2024 | $20.0M | -$11.1M | $-0.22 |
| Q2 2024 | $21.4M | -$12.3M | $-0.25 |
| Q1 2024 | $18.8M | -$16.3M | $-0.33 |
| Q3 2023 | $18.7M | -$13.0M | $-0.27 |
| Q2 2023 | $17.2M | -$14.8M | $-0.30 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Sight Sciences, Inc. Dividends, Buybacks & Capital Allocation
SGHT SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Sight Sciences, Inc. (CIK: 0001531177)
📋 Recent SEC Filings
❓ Frequently Asked Questions about SGHT
What is the AI rating for SGHT?
Sight Sciences, Inc. (SGHT) has an AI rating of SELL with 78% confidence, based on fundamental analysis of SEC EDGAR filings.
What are SGHT's key strengths?
Claude: Exceptional gross margin of 86.2% demonstrates strong product value and pricing power in medical device market. Robust cash position of $92M provides substantial runway and eliminates near-term solvency risk.
What are the risks of investing in SGHT?
Claude: Declining revenue (-3.1% YoY) signals failing commercialization or market demand despite capital availability. Severe operating cash burn (-$29.7M annually) with negative free cash flow unsustainable without revenue recovery.
What is SGHT's revenue and growth?
Sight Sciences, Inc. reported revenue of $77.4M.
Does SGHT pay dividends?
Sight Sciences, Inc. does not currently pay dividends.
Where can I find SGHT SEC filings?
Official SEC filings for Sight Sciences, Inc. (CIK: 0001531177) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is SGHT's EPS?
Sight Sciences, Inc. has a diluted EPS of $-0.74.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is SGHT a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Sight Sciences, Inc. has a SELL rating with 78% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is SGHT stock overvalued or undervalued?
Valuation metrics for SGHT: ROE of -60.1% (sector avg: 15%), net margin of -49.7% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy SGHT stock in 2026?
Our dual AI analysis gives Sight Sciences, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is SGHT's free cash flow?
Sight Sciences, Inc.'s operating cash flow is $-29.7M, with capital expenditures of $224.0K. FCF margin is -38.7%.
How does SGHT compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -49.7% (avg: 12%), ROE -60.1% (avg: 15%), current ratio 10.22 (avg: 2).